Dashboard
Manage Tickers

VTRSViatris Inc

Nasdaq viatris.com


$ 11.11 $ 0.02 (0.18 %)    

Thursday, 18-Apr-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 422.80 $ -2.43 (-0.57 %)
DIA $ 377.76 $ 0.39 (0.1 %)
SPY $ 499.54 $ -1.03 (-0.21 %)
TLT $ 88.82 $ -0.45 (-0.5 %)
GLD $ 220.32 $ 0.75 (0.34 %)
$ 11.12
$ 11.15
$ 0.00 x 0
$ 0.00 x 0
$ 11.07 - $ 11.24
$ 8.53 - $ 13.48
3,464,188
na
13.34B
$ 0.89
$ 243.88
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-28-2024 12-31-2023 10-K
2 11-07-2023 09-30-2023 10-Q
3 08-07-2023 06-30-2023 10-Q
4 05-08-2023 03-31-2023 10-Q
5 02-27-2023 12-31-2022 10-K
6 11-07-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-09-2022 03-31-2022 10-Q
9 02-28-2022 12-31-2021 10-K
10 11-08-2021 09-30-2021 10-Q
11 08-09-2021 06-30-2021 10-Q
12 05-10-2021 03-31-2021 10-Q
13 03-01-2021 12-31-2020 10-K
14 11-10-2020 09-27-2020 10-Q
15 08-12-2020 06-28-2020 10-Q
16 05-12-2020 03-29-2020 10-Q
17 05-07-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

viatris-reports-launch-of-first-bioequivalent-generic-version-of-copaxone-20-mgml-once-daily-in-canada
Viatris Reports Launch Of First Bioequival...
04/15/2024 11:01:49

theramex-says-currently-considering-cmas-decision-in-particular-whether-and-how-best-to-address-competition-concerns-regarding-deal-with-viatris--co-remains-committed-to-offering-women-choice-to-make-empowered-decisions-about-hrt-at-competitive-prices-for-nhs-phase-1-of-cmas-decision-to-have-no-impact-on-cos-ability-to-supply-existing-hrt-products-in-uk
Theramex Says Currently Considering CMA's ...
04/05/2024 16:53:09

- Reuters

Core News & Articles
Ocuphire Announces the US Commercial Launc...
04/01/2024 11:17:13

 Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the ...

viatris-announced-the-us-commercial-launch-of-ryzumvi-phentolamine-ophthalmic-solution-075-for-pharmacologically-induced-mydriasis-ryzumvi-is-now-the-only-us-commercially-available-fda-approved-eye-drop-to-reverse-dilation
Viatris Announced The U.S. Commercial Laun...
04/01/2024 11:00:44

piper-sandler-reiterates-neutral-on-viatris-raises-price-target-to-13
Piper Sandler Reiterates Neutral on Viatri...
03/28/2024 16:22:26

Piper Sandler analyst David Amsellem reiterates Viatris (NASDAQ:VTRS) with a Neutral and raises the price target from $11 to...

looking-into-viatriss-recent-short-interest
Looking Into Viatris's Recent Short Interest
03/15/2024 13:00:14

earlier-on-monday-viatris-mapi-pharma-received-an-fda-complete-response-letter-regarding-the-new-drug-application-for-ga-depot-40mg-the-companies-are-reviewing-the-content-of-the-crl-and-will-be-determining-the-appropriate-next-steps
Earlier On Monday, Viatris' Mapi Pharma Re...
03/11/2024 14:55:54

stocks-fall-ahead-of-feds-inflation-data-unitedhealth-sinks-bitcoin-tops-61000-whats-driving-markets-wednesday
Stocks Fall Ahead Of Fed's Inflation Data,...
02/28/2024 19:08:12

Stocks dipped modestly following a report indicating a marginal downward revision in the U.S. economic growth rate for the last...

viatris-expects-fiscal-year-2024-adjusted-eps-of-270-285-versus-consensus-of-281
Viatris Expects Fiscal Year 2024 Adjusted ...
02/28/2024 11:36:04

viatris-expects-fiscal-year-2024-revenues-of-1525b-1575b-versus-consensus-of-1519b
Viatris Expects Fiscal Year 2024 Revenues ...
02/28/2024 11:35:15

viatris-q4-adjusted-eps-062-misses-065-estimate-sales-383b-miss-387b-estimate
Viatris Q4 Adjusted EPS $0.62 Misses $0.65...
02/28/2024 11:33:43

Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.62 per share which missed the analyst consensus estimate of $0.65 by 4....

earnings-scheduled-for-february-28-2024
Earnings Scheduled For February 28, 2024
02/28/2024 11:24:02

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

viatris-and-idorsia-forge-global-partnership-for-breakthrough-heart-attack-treatments
Viatris And Idorsia Forge Global Partnersh...
02/28/2024 10:20:01

Viatris and Idorsia collaborate on groundbreaking heart attack treatments, leveraging innovative therapies for acute conditions.

Core News & Articles
Viatris And Idorsia Enter Into Significant...
02/28/2024 08:12:18

Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selatogrel and Cenerimod, Both ...

5-value-stocks-in-the-healthcare-sector
5 Value Stocks In The Healthcare Sector
02/26/2024 14:44:21

uks-cma-says-launch-of-theramexviatris-merger-inquiry-by-notice-to-the-parties
UK's CMA Says Launch Of Theramex/Viatris M...
02/06/2024 14:13:27

-Reuters

vtrs---analyzing-viatriss-short-interest
(VTRS) - Analyzing Viatris's Short Interest
01/23/2024 14:00:18

Core News & Articles
Watching Alight, Inc., Viatris Inc.; Trade...
01/22/2024 16:15:51

regeneron-pharmas-pipeline-makes-this-analyst-turn-bullish
Regeneron Pharma's Pipeline Makes This Ana...
01/12/2024 15:18:10

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) won a lawsuit last month against Viatris Inc (NASDAQ: VTRS)

beat-inflation-with-these-3-high-yielding-dividend-stocks-in-health-care-sector-from-wall-streets-most-accurate-analysts
Beat Inflation With These 3 High-Yielding ...
01/12/2024 13:26:26

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often com...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

04/22/2024 Dick's Sporting Goods, Inc. (DKS)
04/22/2024 Innodata Inc. (INOD)
04/22/2024 Fox Factory Holding Corp. (FOXF)
04/23/2024 Lantronix, Inc. (LTRX)

NEW CASE INVESTIGATION

AnaptysBio Inc (ANAB)